Published Online: June 30, 2014
Dr Sonnad inquired how replacing brand drugs with generic equivalents can affect pathway adherence. She also asked panelists to discuss the differences between early-stage and late-stage disease regimens, as well as the degree of flexibility there is in regimen design.
Dr Nabhan said providers’ participation in pathway development is essential. They are likely to offer a variety of critical contributions and recommendations, including the ability to recognize the nuances between early-stage and late-stage disease states.
Dr Yu said that documentation is not only key to regimen flexibility, but to monitor pathway toxicity. Developing regimens can also vary, more greatly for late-stage disease than it does for early-stage disease.
Dr Tischler said this disease state variation also means that regimens can be flexible. As a disease becomes more complex, however, it may be difficult to offer generic medications.
Dr Nabhan said pathways may need to adapt to newer medications, but there needs to be data to support their effectiveness so that they can be be included in a regimen.